Olink®Part of Thermo Fisher Scientific
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights
A unique combination of specificity and scalability enables high-throughput, multiplex protein biomarker analysis.
Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets.
Join the growing global community and consortia of Olink users to empower your biomarker discovery.
Over 3,000 and growing rapidly – covering all major disease areas
Your source for Olink’s terms, privacy policies, and compliance details
Filters
Circulation: Genomic and Precision Medicine, 2023Plasma Protein Profiling of Incident Cardiovascular Diseases: A Multisample Evaluation
Lind L., Titova O., Zeng R. et al.
Olink Target 96
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023Plasma neurofilament light levels show elevation two years prior to diagnosis of amyotrophic lateral sclerosis in the UK Biobank
Smith E., Lee J., Prilutsky D. et al.
Olink Explore 3072/384
ESC Heart Failure, 2023Sex‐specific cardiovascular protein levels and their link with clinical outcome in heart failure
de Bakker M., Loncq de Jong M., Petersen T. et al.
Journal of Thrombosis and Haemostasis, 2023Proteomic insights into modifiable risk of venous thromboembolism and cardiovascular comorbidities
Yuan S., Xu F., Zhang H. et al.
Scientific Reports, 2023Changes in natural killer and T lymphocyte phenotypes in response to cardiovascular risk management
Good E., Åkerman L., Nyström S. et al.
Pediatric Research, 2023Antisecretory factor in breastmilk is associated with reduced incidence of sepsis in preterm infants
Gustafsson A., Johansson E., Henckel E. et al.
Nature Communications, 2023Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation
Mälarstig A., Grassmann F., Dahl L. et al.
iScience, 2023Hospital-treated prevalent infections, the plasma proteome and incident dementia among UK older adults
Beydoun M., Beydoun H., Noren Hooten N. et al.
Frontiers in Immunology, 2023Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay
Kmezic I., Gustafsson R., Fink K. et al.
iScience, 2023Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion
Moaddel R., Farmer C., Yavi M. et al.
Brain, 2023Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains
Quesnel M., Labonté A., Picard C. et al.
Scientific Reports, 2023Galectin-4 is associated with diabetes and obesity in a heart failure population
Dieden A., Gudmundsson P., Korduner J. et al.
Scientific Reports, 2023Dysregulations in hemostasis, metabolism, immune response, and angiogenesis in post-acute COVID-19 syndrome with and without postural orthostatic tachycardia syndrome: a multi-omic profiling study
Mahdi A., Zhao A., Fredengren E. et al.
Frontiers in Immunology, 2023Olink proteomics analysis uncovers the landscape of inflammation-related proteins in patients with acute compartment syndrome
Wang T., Yang S., Long Y. et al.
Molecular Neurobiology, 2023Causal Association of Cytokines and Growth Factors with Stroke and Its Subtypes: a Mendelian Randomization Study
Chen G., Lin T., Wu M. et al.
European Journal of Cancer, 2023FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction
van Eijck C., Strijk G., Vietsch E. et al.
Scientific Reports, 2023Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study
Mynster Kronborg T., Webel H., O’Connell M. et al.
Journal of Applied Physiology, 2023Type 2 diabetes exacerbates changes in blood pressure-independent arterial stiffness: cross-sectional and longitudinal evidence from the SUMMIT study
Aizawa K., Gates P., Mawson D. et al.
Translational Neurodegeneration, 2023A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Faridar A., Eid A., Thome A. et al.
Olink Target 48
European Journal of Heart Failure, 2023Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program
Ferreira J., Packer M., Butler J. et al.
3168 publications
Items per page
1601-1620 of 3168 publications